/
NBIX
$152.72+$1.90 (+1.26%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$15.9B
102M shares
52-week range
$122.14 – $186.12
48% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change+$62.54
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
www.neurocrine.com- Employees
- 2,500
- IPO / List date
- May 23, 1996
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds NBIX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,418,897 | $318.7M |
| Bridgewater Associatesas of 2026-03-31 | 148,141 | $19.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NBIX yet.
